AMENDMENT TO MENON- CELLCEUTIX AGREEMENT WITHOUT CHANGING THE TOTAL AMOUNT OF ROYALTIES PAYABLE UNDER THE TERMS OF THE PRIOR AGREEMENTPrior Agreement • September 2nd, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
This Amendment, effective on signature of the last party to sign (“Effective Date”), between Dr. Krishna Menon, (hereinafter “Menon”) and Cellceutix Corporation, a Nevada corporation located at 100 Cummings Center, Suite 151, Beverly MA 01915 USA (hereinafter “Cellceutix”), amends a prior agreement between these parties dated October 17, 2007 (“Prior Agreement” Attachment A hereto), by which Menon assigned to Cellceutix all right, title and interest to a Compound (as defined therein) and patents thereon in consideration for a percentage of Net Sales of the Compound, also known as Kevetrin.
AGREEMENTAgreement • September 2nd, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
IN THIS AGREEMENT, Cellceutix Corporation, a Nevada corporation (“Cellceutix”), and Wayne O. Aruda, (“Aruda”), Aruda Inc. dba Agrenetics, a Massachusetts corporation (“Agrenetics”), (each of Cellceutix, Aruda, and Agrenetics being a “Party”), agree as follows:
ASSIGNMENTAgreement • September 2nd, 2014 • Cellceutix CORP • Pharmaceutical preparations • Massachusetts
THIS AGREEMENT, effective on the date of last signature hereof (“Effective Date”), is by and between Dr. Krishna Menon, an individual residing at 10 Bridle Way, N. Reading, MA 01864 (hereinafter “Menon”) and Cellceutix Corporation, a Nevada corporation located at 100 Cummings Center, Suite 151, Beverly MA 01915 USA (hereinafter “Cellceutix”).
